Bionano Genomics Projects Q4 2025 Revenue of $7.5 to $7.9 Million
Bionano Genomics Inc. projects Q4 2025 revenue between $7.5 and $7.9 million, following a 21% increase in Q3 revenue to $7.4 million. Growth was driven by a rise in consumables, software revenues, and nanochannel array flowcell sales. The company improved its gross margin to 46% and expects over 25 new OGM system installations in 2025, surpassing expectations.
Bionano Genomics Inc. has initiated fourth quarter 2025 revenue guidance in the range of $7.5 to $7.9 million, building on its third quarter results. For the third quarter ended September 30, 2025, the company reported total revenue of $7.4 million, marking a 21% increase from $6.1 million in the same period of the previous year. This growth was driven by a 15% rise in consumables and software revenues and a 7% increase in nanochannel array flowcell sales. The company also reported improved gross margin of 46%, a significant turnaround from negative margins in the prior year period. Additionally, Bionano expects new OGM system installations for the full year 2025 to surpass 25, exceeding previous expectations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionano Genomics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001411690-25-000092), on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
